186 related articles for article (PubMed ID: 25343529)
1. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Brindisi M; Butini S; Franceschini S; Brogi S; Trotta F; Ros S; Cagnotto A; Salmona M; Casagni A; Andreassi M; Saponara S; Gorelli B; Weikop P; Mikkelsen JD; Scheel-Kruger J; Sandager-Nielsen K; Novellino E; Campiani G; Gemma S
J Med Chem; 2014 Nov; 57(22):9578-97. PubMed ID: 25343529
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
3. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
[TBL] [Abstract][Full Text] [Related]
5. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
7. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
8. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
9. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Xiamuxi H; Wang Z; Li J; Wang Y; Wu C; Yang F; Jiang X; Liu Y; Zhao Q; Chen W; Zhang J; Xie Y; Hu T; Xu M; Guo S; Akber Aisa H; He Y; Shen J
Bioorg Med Chem; 2017 Sep; 25(17):4904-4916. PubMed ID: 28774576
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
Chen Y; Wang S; Xu X; Liu X; Yu M; Zhao S; Liu S; Qiu Y; Zhang T; Liu BF; Zhang G
J Med Chem; 2013 Jun; 56(11):4671-90. PubMed ID: 23675993
[TBL] [Abstract][Full Text] [Related]
12. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
13. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
[TBL] [Abstract][Full Text] [Related]
14. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
15. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.
Kuroki T; Meltzer HY; Ichikawa J
J Pharmacol Exp Ther; 1999 Feb; 288(2):774-81. PubMed ID: 9918588
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Sun H; Zhu L; Yang H; Qian W; Guo L; Zhou S; Gao B; Li Z; Zhou Y; Jiang H; Chen K; Zhen X; Liu H
Bioorg Med Chem; 2013 Feb; 21(4):856-68. PubMed ID: 23332346
[TBL] [Abstract][Full Text] [Related]
17. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
[TBL] [Abstract][Full Text] [Related]
18. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex.
Ohoyama K; Yamamura S; Hamaguchi T; Nakagawa M; Motomura E; Shiroyama T; Tanii H; Okada M
Eur J Pharmacol; 2011 Feb; 653(1-3):47-57. PubMed ID: 21147094
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug.
Xu Y; Zhu X; Wang H; Sun S; Yue X; Tian J
Sci Rep; 2018 May; 8(1):6892. PubMed ID: 29720711
[TBL] [Abstract][Full Text] [Related]
20. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
Weiner DM; Burstein ES; Nash N; Croston GE; Currier EA; Vanover KE; Harvey SC; Donohue E; Hansen HC; Andersson CM; Spalding TA; Gibson DF; Krebs-Thomson K; Powell SB; Geyer MA; Hacksell U; Brann MR
J Pharmacol Exp Ther; 2001 Oct; 299(1):268-76. PubMed ID: 11561089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
